Name: Latest research reports of Lupin Ltd. authored by KRChoksey and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 5
Author: KRChoksey

Focus on complex portfolio to drive growth

Buy: Lupin Ltd.

Target

KRChoksey

Lupin’s revenue was largely in-line with our estimates (+2.3%). EBITDA and Adj. PAT beat our estimates significantly due to lower-than-expected COGS and lower than expected other expenses.
We increase our FY2E6 EPS estimates to INR 79.7 (previously: 78.8) as we anticipate expanding respiratory portfolio in Europe, upcoming injectable launches include glucagon and dalbavancin, and GLP-1 launch in India in 2026E will drive growth.